Market Overview

Aegis Capital Maintains Buy on Trius Therapeutics, Inc., Lowers PT to $14.00

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Latest Ratings for TSRX

DateFirmActionFromTo
Sep 2013Aegis CapitalTerminatesNot Rated
Aug 2013Guggenheim SecuritiesDowngradesBuyNeutral
Aug 2013Aegis CapitalDowngradesBuyHold

View More Analyst Ratings for TSRX
View the Latest Analyst Ratings

Posted-In: News Price Target Analyst Ratings

 

Related Articles (TSRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters